Connect with us


COVID-19: Oxford varsity develop year-long protection drug



TRIALS currently ongoing in the United Kingdom have revealed a coronavirus vaccine being developed in the UK to be capable of providing protection against the disease “for about a year”.

  According to the drugmaker, human trials of the vaccine are under way, with the firm already having reached agreements to supply around two billion doses across the world.

  AstraZeneca has joined forces with the UK government to support a COVID-19 vaccine developed by the University of Oxford.

  AstraZeneca’s Chief Executive, Pascal Soriot, , told Belgian radio today that a phase one trial of the vaccine in Britain was due to end soon, while a phase three trial has already begun.

  A phase three trial is usually the final phase in the clinical development of a vaccine and sees the vaccine given to thousands of people to be tested for efficacy and safety.

  Commenting on the likely protection the Oxford vaccine will provide, Soriot said, “We think that it will protect for about a year, “adding that “if all goes well, we will have the results of the clinical trials in August or September. We are manufacturing in parallel. We will be ready to deliver from October, if all goes well.”

  Recall that AstraZeneca has previously acknowledged the vaccine may not work, despite its commitments to progress its clinical programme and to scale up manufacturing.

  The University of Oxford vaccine, now known as AZD1222, is based on a weakened version of the common cold that causes infections in chimpanzees.

It also contains the genetic material of the spike protein of SARS-CoV-2 – the strain of coronavirus that causes the COVID-19 illness.

  After vaccination, the immune system is primed to attack COVID-19 if it later infects the body.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *